Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cartesian Therapeutics Inc. (RNAC) Stock Chart
Cartesian Therapeutics (RNAC) has a latest price of $6.12 on Nov 17, 2026, 44.4% below its 52-week high of $11.00. Its price fell 18.0% over the past 12 months. The month-end price fell 98.8% over the 10 years through Oct 2026, a compound annual decline of 35.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $637.24 in Oct 2017 and its lowest $6.15 in Mar 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RNAC with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RNAC.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 41.7%, and over 6 months it rose 0.5%. The month-end price fell 82.7% over the 3 years through Oct 2026, a compound annual decline of 44.3%.
| Period | Change |
|---|---|
| 1 month | +0.7% |
| 3 months | -41.7% |
| 6 months | +0.5% |
| 12 months | -18.0% |
| 12 months, with dividends | -18.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -82.7% | -44.3% |
| 5 years | -94.0% | -43.0% |
| 10 years | -98.8% | -35.6% |
Price by Year
Its best calendar year was 2020, when the price rose 27.3%, and its weakest was 2018, when it fell 72.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $6.49 | -10.0% |
| 2025 | $7.21 | -59.7% |
| 2024 | $17.91 | -13.5% |
| 2023 | $20.70 | -39.0% |
| 2022 | $33.93 | -65.3% |
| 2021 | $97.90 | +7.6% |
| 2020 | $90.99 | +27.3% |
| 2019 | $71.47 | -10.5% |
| 2018 | $79.88 | -72.9% |
| 2017 | $294.59 | -42.8% |
Trading Range
The price is 12.9% below its 50-day average of $7.02 and 19.5% below its 200-day average of $7.61.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $6.12 | |
| 52-week high | $11.00 | -44.4% |
| 52-week low | $5.60 | +9.3% |
| 50-day average | $7.02 | -12.9% |
| 200-day average | $7.61 | -19.5% |
Price Risk
Over 3 years, its largest fall from a peak was 85.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.35 |
| Largest fall, 1 year | -42.6% |
| Largest fall, 3 years | -85.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RNAC
What is RNAC's 1-year price change?
Cartesian Therapeutics's price fell 18.0% over the past 12 months. With dividends included, the 12-month total return was -18.0%.
What is RNAC's 5-year price change?
Cartesian Therapeutics's month-end price fell 94.0% over the 5 years through Oct 2026, a compound annual decline of 43.0%. These figures leave out dividends.
What is RNAC's 52-week high and low?
Cartesian Therapeutics's 52-week high is $11.00 and its 52-week low is $5.60. Its latest price of $6.12 on Nov 17, 2026 is 44.4% below the high.
What is RNAC's beta?
Cartesian Therapeutics's 1-year beta against the S&P 500 is 1.35, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 42.6%.
Is the RNAC chart free?
Yes. Advanced Charting for RNAC is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RNAC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors